Shanghai Universal Biotech301166.SZValuation Analysis

As of Oct 19, 2026, Shanghai Universal Biotech (301166.SZ) trades at a negative P/E (-125.43x, due to a recent net loss), P/B of 1.39x, P/S of 2.36x, and a dividend yield of 1.91%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 51st percentile over the trailing 10Y window (vs. 79th percentile over 3Y); P/S sits at the 26th percentile over the trailing 10Y window (vs. 41st percentile over 3Y).
Cross-sectional valuation: its P/B ranks at the 17th percentile within its industry and the 18th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.59%, ranking at the 88th percentile over the trailing 20Y window.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 1.91% comes from cash dividends, with an implied ~0.68% from buybacks — a fairly balanced mix of both channels. Shanghai Universal Biotech operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.